-

11:06:11 PM

VYNE Stock News

VYNE - VYNE Therapeutics Inc

11/18/22 8:00 AM

Nasdaq : VYNE

conferences

VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David

RHEA-AI

neutral

11/17/22 8:00 AM

Nasdaq : VYNE

clinical trial

VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the

RHEA-AI

neutral

11/10/22 4:01 PM

Nasdaq : VYNE

earnings

VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and development of oral, BD2 selective VYN202 program Expanded analysis of FMX114 Phase 2a trial results suggests FMX114

RHEA-AI

neutral

09/06/22 8:00 AM

Nasdaq : VYNE

conferences

VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today

RHEA-AI

neutral

08/12/22 8:00 AM

Nasdaq : VYNE

earnings

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results

RHEA-AI

negative

08/10/22 8:32 AM

Nasdaq : VYNE

clinical trial

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced results from the

RHEA-AI

neutral

07/19/22 8:00 AM

Nasdaq : VYNE

conferences

VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart,

RHEA-AI

neutral

06/17/22 8:00 AM

Nasdaq : VYNE

clinical trial

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of

RHEA-AI

neutral

05/18/22 8:00 AM

Nasdaq : VYNE

conferences

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : VYNE

earnings

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBET TM BET inhibitor platform on May 17 th BRIDGEWATER, N.J., May 12, 2022

RHEA-AI

neutral

1 2 3 4 5 6 7 Next